Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5172706
Max Phase: Preclinical
Molecular Formula: C34H60F3N11O9
Molecular Weight: 709.89
Associated Items:
ID: ALA5172706
Max Phase: Preclinical
Molecular Formula: C34H60F3N11O9
Molecular Weight: 709.89
Associated Items:
Canonical SMILES: N=C(N)N[C@@H]1CCOCNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2CCCCC2)NC(=O)CCNC(=O)CNC1=O.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C32H59N11O7.C2HF3O2/c33-14-6-4-10-22-29(47)39-20-50-17-13-24(43-32(35)36)28(46)38-19-27(45)37-16-12-26(44)40-25(18-21-8-2-1-3-9-21)31(49)42-23(30(48)41-22)11-5-7-15-34;3-2(4,5)1(6)7/h21-25H,1-20,33-34H2,(H,37,45)(H,38,46)(H,39,47)(H,40,44)(H,41,48)(H,42,49)(H4,35,36,43);(H,6,7)/t22-,23-,24+,25+;/m0./s1
Standard InChI Key: GAMPLFDDPCNJMI-UDRIRSMNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 709.89 | Molecular Weight (Monoisotopic): 709.4599 | AlogP: -2.36 | #Rotatable Bonds: 11 |
Polar Surface Area: 297.77 | Molecular Species: BASE | HBA: 10 | HBD: 11 |
#RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.68 | CX Basic pKa: 11.05 | CX LogP: -4.15 | CX LogD: -11.22 |
Aromatic Rings: 0 | Heavy Atoms: 50 | QED Weighted: 0.06 | Np Likeness Score: 0.62 |
1. Huber S, Braun NJ, Schmacke LC, Quek JP, Murra R, Bender D, Hildt E, Luo D, Heine A, Steinmetzer T.. (2022) Structure-Based Optimization and Characterization of Macrocyclic Zika Virus NS2B-NS3 Protease Inhibitors., 65 (9.0): [PMID:35475620] [10.1021/acs.jmedchem.1c01860] |
Source(1):